Clinical Trials Browser

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Phase 3 Active not recruiting

5,018 enrolled 14 charts

Breast

Carcinoma, Intraductal, Noninfiltrating

NCT02311933 2026-04-13

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Active not recruiting

81 enrolled 9 charts

Breast

Breast Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast

Breast Neoplasms

NCT05659563 2026-03-19

EMPRESS

Phase 2 Completed

92 enrolled 14 charts

Breast

Breast Neoplasms

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast

Breast Cancer Metastatic

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Phase 2 Completed

41 enrolled 9 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1 Terminated

4 enrolled 11 charts

Breast

Breast Neoplasms

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Phase 2 Completed

19 enrolled 10 charts

Breast

Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00066690 2026-02-06

SOFT

Phase 3 Completed

3,066 enrolled 15 charts

Breast

Breast Neoplasms

NCT00066703 2026-02-06

TEXT

Phase 3 Completed

2,672 enrolled 14 charts

Breast

Breast Neoplasms

NCT02747004 2026-02-06

Next MONARCH 1

Phase 2 Active not recruiting

234 enrolled 20 charts

Breast

Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Phase 2 Active not recruiting

53 enrolled 13 charts

Breast

Breast Neoplasms

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

49 enrolled 14 charts

Breast

Breast Neoplasms

NCT01196936 2026-01-05

LDTam

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast

Breast Neoplasms

NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Phase 2/3 Completed

260 enrolled 20 charts

Cystadenocarcinoma, Serous

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast

Breast Neoplasms

NCT04272801 2025-10-22

POWER

Phase 2 Active not recruiting

84 enrolled 9 charts

Breast

Breast Neoplasms

NCT05128773 2025-09-16

AMEERA-6

Phase 3 Terminated

3 enrolled 3 charts

Breast

Breast Neoplasms

NCT00601900 2025-05-23

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Phase 3 Completed

394 enrolled 11 charts

Breast

Breast Neoplasms

NCT02764541 2025-05-07

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Phase 2 Active not recruiting

195 enrolled 26 charts

Breast

Breast Neoplasms, Carcinoma, Lobular

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2 Completed

162 enrolled 12 charts

Breast

Breast Neoplasms

NCT03219476 2025-04-29

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Phase 2 Completed

37 enrolled 10 charts

Breast

Breast Neoplasms

Clinical Trials

TAILORx

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

EMPRESS

AMEERA-3

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

e3

SOFT

TEXT

Next MONARCH 1

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

LDTam

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

MORPHEUS HR+BC

POWER

AMEERA-6

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer